Clinical Characteristics and Risk Factors for Severe Outcomes of Novel Coronavirus Infection, January-March 2020, Japan.


Journal

Journal of epidemiology
ISSN: 1349-9092
Titre abrégé: J Epidemiol
Pays: Japan
ID NLM: 9607688

Informations de publication

Date de publication:
05 08 2021
Historique:
pubmed: 1 6 2021
medline: 10 8 2021
entrez: 31 5 2021
Statut: ppublish

Résumé

Notifications of novel coronavirus infections increased in early 2020 in Japan. We described characteristics of novel coronavirus infection cases and analyzed risk factors for severe outcomes. Cases were persons with laboratory-confirmed novel coronavirus infection reported under national surveillance between January and March 2020. Clinical characteristics were described, and risk factors of (1) intensive care unit [ICU] admission and (2) invasive ventilation/death were analyzed using Poisson regression. Among the 516 cases analyzed, median age was 60 years (range: 1-97 years) and 285 (55%) were male. Common symptoms/signs were fever (375/475, 79%), cough (353/465, 76%), and pneumonia (245/387, 63%). Ten (2%) cases died. Of the 348 cases with data, 50 (14%) required invasive ventilation. Adjusted for each other, male gender and 1-year increase in age were associated with ICU admission (risk ratio [RR] 4.18; 95% confidence interval [CI], 1.69-10.32 and RR 1.05; 95% CI, 1.03-1.08, respectively) and invasive ventilation/death (RR 2.79; 95% CI, 1.49-5.21 and RR 1.06; 95% CI, 1.04-1.08, respectively). Diabetes, dyslipidemia, hyperuricemia, and lung diseases were also associated with severe outcomes. Of the 80 cases asymptomatic at hospitalization, 40 developed symptoms and five of them >70 years of age required invasive ventilation. The early stage of the novel coronavirus epidemic in Japan disproportionately affected the elderly. Older age, male gender, and underlying conditions were associated with severe outcomes. Notably, some elderly case-patients who were asymptomatic at diagnosis and promptly hospitalized still went on to develop severe disease, indicating the importance of careful monitoring of certain populations.

Sections du résumé

BACKGROUND
Notifications of novel coronavirus infections increased in early 2020 in Japan. We described characteristics of novel coronavirus infection cases and analyzed risk factors for severe outcomes.
METHODS
Cases were persons with laboratory-confirmed novel coronavirus infection reported under national surveillance between January and March 2020. Clinical characteristics were described, and risk factors of (1) intensive care unit [ICU] admission and (2) invasive ventilation/death were analyzed using Poisson regression.
RESULTS
Among the 516 cases analyzed, median age was 60 years (range: 1-97 years) and 285 (55%) were male. Common symptoms/signs were fever (375/475, 79%), cough (353/465, 76%), and pneumonia (245/387, 63%). Ten (2%) cases died. Of the 348 cases with data, 50 (14%) required invasive ventilation. Adjusted for each other, male gender and 1-year increase in age were associated with ICU admission (risk ratio [RR] 4.18; 95% confidence interval [CI], 1.69-10.32 and RR 1.05; 95% CI, 1.03-1.08, respectively) and invasive ventilation/death (RR 2.79; 95% CI, 1.49-5.21 and RR 1.06; 95% CI, 1.04-1.08, respectively). Diabetes, dyslipidemia, hyperuricemia, and lung diseases were also associated with severe outcomes. Of the 80 cases asymptomatic at hospitalization, 40 developed symptoms and five of them >70 years of age required invasive ventilation.
CONCLUSIONS
The early stage of the novel coronavirus epidemic in Japan disproportionately affected the elderly. Older age, male gender, and underlying conditions were associated with severe outcomes. Notably, some elderly case-patients who were asymptomatic at diagnosis and promptly hospitalized still went on to develop severe disease, indicating the importance of careful monitoring of certain populations.

Identifiants

pubmed: 34053961
doi: 10.2188/jea.JE20200519
pmc: PMC8275442
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

487-494

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Infez Med. 2020 Dec 1;28(4):469-474
pubmed: 33257620
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1463-1465
pubmed: 32771919
BMJ. 2020 Mar 26;368:m1198
pubmed: 32217618
BMC Public Health. 2011 Nov 02;11:841
pubmed: 22044598
N Engl J Med. 1999 Jan 14;340(2):115-26
pubmed: 9887164
Clin Infect Dis. 2021 May 18;72(10):e558-e565
pubmed: 32856034
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Infect. 2020 Nov;81(5):e3-e5
pubmed: 32920063
Clin Infect Dis. 2021 May 4;72(9):e206-e214
pubmed: 32674114
Clin Infect Dis. 2020 Mar 16;:
pubmed: 32173725
Emerg Infect Dis. 2020 Jul;26(7):
pubmed: 32275498
Euro Surveill. 2020 Jun;25(23):
pubmed: 32553062
Clin Infect Dis. 2021 Jun 1;72(11):e695-e703
pubmed: 32945846
MMWR Morb Mortal Wkly Rep. 2020 Jul 03;69(26):841-846
pubmed: 32614810
J Med Virol. 2021 May;93(5):2925-2931
pubmed: 33463731
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):312-313
pubmed: 32191689
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
Eur J Nucl Med Mol Imaging. 2020 Jul;47(7):1649-1656
pubmed: 32342191
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Am J Obstet Gynecol MFM. 2020 May;2(2):100118
pubmed: 32292903
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
Biosci Trends. 2020 Jul 17;14(3):206-208
pubmed: 32321904
J Korean Med Sci. 2020 Sep 21;35(37):e333
pubmed: 32959547
Pathologe. 2020 Dec;41(Suppl 2):99-102
pubmed: 33306138
Sci China Life Sci. 2020 May;63(5):706-711
pubmed: 32146694
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Clin Microbiol Infect. 2020 Jul;26(7):957-959
pubmed: 32234453
CMAJ. 2012 May 15;184(8):895-9
pubmed: 22158397
Atherosclerosis. 2018 Nov;278:226-231
pubmed: 30326405

Auteurs

Yuuki Tsuchihashi (Y)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases (NIID).

Yuzo Arima (Y)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases (NIID).

Takuri Takahashi (T)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases (NIID).

Kazuhiko Kanou (K)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases (NIID).

Yusuke Kobayashi (Y)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases (NIID).

Tomimasa Sunagawa (T)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases (NIID).

Motoi Suzuki (M)

Infectious Disease Surveillance Center, National Institute of Infectious Diseases (NIID).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH